The critical phase of Walgreens’ acquisition by Sycamore Partners has concluded successfully, with bondholders delivering overwhelming approval for the transaction. The exchange offer for outstanding bonds expired today, having achieved exceptionally high acceptance rates that signal near-unanimous creditor support for the deal.
Near-Unanimous Creditor Approval Paves Way for Acquisition
Bond investors have demonstrated remarkable consensus, with acceptance rates reaching as high as 98% for the exchange offer. This broad support effectively removes one of the final significant obstacles in the acquisition process and facilitates the planned capital restructuring. The final settlement is scheduled for August 26, which coincides with the anticipated completion of the entire transaction.
This decisive outcome follows earlier shareholder approval, where 96% of voting shares endorsed the takeover. The bondholders’ strong participation in the exchange offer confirms that the path is clear for the complete acquisition by Blazing Star Parent, LLC. The withdrawal deadline for already submitted bonds has now passed, making the creditors’ decision final and irreversible.
Should investors sell immediately? Or is it worth buying Walgreens?
Business Operations Continue Amid Ownership Transition
While the ownership transition progresses, Walgreens continues to advance its core business operations. The company’s Specialty Pharmacy division has significantly expanded its limited distribution drug network, which now includes 265 products. New therapies addressing HIV prevention, chronic skin conditions, and specific forms of leukemia are expected to further strengthen this profitable specialty segment.
Today’s deadline milestone not only concludes Walgreens’ era as a publicly traded company but also confirms the pharmaceutical giant’s strategic direction under new ownership. The successful bond exchange represents the final major step in solidifying the acquisition that will reshape the company’s future trajectory.
Ad
Walgreens Stock: Buy or Sell?! New Walgreens Analysis from November 20 delivers the answer:
The latest Walgreens figures speak for themselves: Urgent action needed for Walgreens investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 20.
Walgreens: Buy or sell? Read more here...
